Deferiprone (Standard)

Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[30652-11-0]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; COX; Ferroptosis; HCV; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Infection; Endocrinology; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/deferiprone-standard.html

Purity

99.99

Smiles

O=C1C(O)=C(C)N(C)C=C1

Molecular Formula

C7H9NO2

Molecular Weight

139.15

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Kontoghiorghes GJ, et al. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26 (8) :553-584.|[2]Rui V. Simões, Inhibition of prostate cancer proliferation by Deferiprone. NMR Biomed|[3]Oded Shalev. et al. Deferiprone (L1) Chelates Pathologic Iron Deposits From Membranes of Intact Thalassemic and Sickle Red Blood Cells Both In Vitro and In Vivo.|[4]Ngan Thi Tran, et al. Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition. Platelets 2020 May 18;31 (4) :505-512. |[5]Andrea Pagani, MD, et al. Deferiprone Stimulates Aged Dermal Fibroblasts via HIF-1α Modulation.Pathog Dis. 2018 Jul 1;76 (5) .|[6]Débora C Coraça-Huber, et al. Iron chelation destabilizes bacterial biofilms and potentiates the antimicrobial activity of antibiotics against coagulase-negative Staphylococci. Pathogens and Disease, Volume 76, Issue 5, July 2018, fty052|[7]Shalini S. Rao, et al. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. Neurotherapeutics. 2021 Apr;18 (2) :1081-1094.|[8]Makhdoumi P, et al. Oral deferiprone administration ameliorates cisplatin-induced nephrotoxicity in rats.J Pharm Pharmacol. 2018 Oct;70 (10) :1357-1368. |[9]Yanan Zhang, et al. Taurine and deferiprone against Al-linked apoptosis in rat hippocampus. J Trace Elem Med Biol. 2023 Mar;76:127113.